Cost-effectiveness of lecanemab for early Alzheimer disease
- VernacularTitle:仑卡奈单抗治疗早期阿尔茨海默病的药物经济学评价
- Author:
Chaogang XIONG
1
;
Junsong WEI
2
;
Mengna AN
2
;
Zijie DENG
1
;
Lei DU
1
;
Qian LEI
1
;
Xin ZHANG
1
;
Shengjie ZHANG
1
;
Wenbing MA
2
;
Weiyi FENG
2
Author Information
1. Dept. of Pharmacy，Xi’an Chest Hospital，Xi’an 710100，China
2. Dept. of Pharmacy，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China
- Publication Type:Journal Article
- Keywords:
Alzheimer disease;
lecanemab;
cost-effectiveness;
pharmacoeconomics
- From:
China Pharmacy
2026;37(13):1735-1739
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of lecanemab for early Alzheimer disease （AD） from a whole-society perspective. METHODS Based on data from the Clarity AD study， a global multicenter， randomized， double-blind， placebo-controlled study of lecanemab for early AD， a Markov model was developed according to the disease progression of AD， with a monthly cycle and a time horizon extending to 99% patient mortality. Quality-adjusted life year （QALY） and incremental cost-effectiveness ratio （ICER） were used as outcome indicators， with a willingness-to-pay （WTP） threshold set at twice China’s per capita gross domestic product （GDP） for 2025 （199 330.00 yuan/QALY）. The model simulated the cost-effectiveness of lecanemab plus standard of care （SoC） versus placebo plus SoC for early AD. One-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis were employed to test the robustness of the results. RESULTS Compared with placebo plus SoC， the ICER for lecanemab plus SoC was 4 364 711.54 yuan/QALY. One-way sensitivity analysis showed that the hazard ratio for disease progression， the price of lecanemab， body weight， the monthly progression probability of mild cognitive impairment， and the discount rate were key parameters affecting model robustness. Results of the probabilistic sensitivity analysis showed that the probability of lecanemab being cost-effective was 0 at the current WTP threshold. Scenario analysis indicated that a price reduction of at least 94.88% would be required for lecanemab to fall below the WTP threshold. CONCLUSIONS At the current WTP threshold， lecanemab plus SoC is not cost-effective compared with placebo plus SoC for early AD.
